Non-myeloablative Conditioning is Sufficient to Achieve Complete Donor Myeloid Chimerism Following Matched Sibling Donor Bone Marrow Transplant for Myeloproliferative Leukemia Virus Oncogene () Mutation-driven Congenital Amegakaryocytic...

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2022 Aug 15

PMID 35967582

Authors

Joseph Hai Oved

Yash B Shah

Kimberly Venella

Michele E Paessler

Timothy S Olson

Affiliations

Soon will be listed here.

Abstract

Background: Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare platelet production disorder caused mainly by loss of function biallelic mutations in myeloproliferative leukemia virus oncogene (), the gene encoding the thrombopoietin receptor (TPOR). Patients with -mutant CAMT are not only at risk for life-threatening bleeding events, but many affected individuals will also ultimately develop bone marrow aplasia owing to the absence of thrombopoietin/TPOR signaling required for maintenance of hematopoietic stem cells. Curative allogeneic stem cell transplant for patients with CAMT has historically used myeloablative conditioning; however, given the inherent stem cell defect in -mutant CAMT, a less intensive regimen may prove equally effective with reduced morbidity, particularly in patients with evolving aplasia.

Methods: We report the case of a 2-year-old boy with -mutant CAMT and bone marrow hypocellularity who underwent matched sibling donor bone marrow transplant (MSD-BMT) using a non-myeloablative regimen consisting of fludarabine, cyclophosphamide, and antithymocyte globulin (ATG).

Results: The patient achieved rapid trilinear engraftment and resolution of thrombocytopenia. While initial myeloid donor chimerism was mixed (88% donor), due to the competitive advantage of donor hematopoietic cells, myeloid chimerism increased to 100% by 4 months post-transplant. Donor chimerism and blood counts remained stable through 1-year post-transplant.

Conclusion: This experience suggests that non-myeloablative conditioning is a suitable approach for patients with -mutant CAMT undergoing MSD-BMT and is associated with reduced risks of conditioning-related toxicity compared to traditional myeloablative regimens.

References

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A . c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1):139-46. DOI: 10.1182/blood.v97.1.139. View

Tarek N, Kernan N, Prockop S, Scaradavou A, Small T, OReilly R . T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia. Bone Marrow Transplant. 2011; 47(5):744-6. DOI: 10.1038/bmt.2011.142. View

Deeg H, Leisenring W, Storb R, NIMS J, Flowers M, Witherspoon R . Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998; 91(10):3637-45. View

Clark R, Mostoufi-Moab S, Yasui Y, Vu N, Sklar C, Motan T . Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE). Lancet Oncol. 2020; 21(3):436-445. PMC: 7060129. DOI: 10.1016/S1470-2045(19)30818-6. View

Al-Qahtani F . Congenital amegakaryocytic thrombocytopenia: a brief review of the literature. Clin Med Insights Pathol. 2010; 3:25-30. PMC: 2999995. DOI: 10.4137/cpath.s4972. View

Maserati E, Panarello C, Morerio C, Valli R, Pressato B, Patitucci F . Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498). Haematologica. 2008; 93(8):1271-3. DOI: 10.3324/haematol.12748. View

Cancio M, Hebert K, Kim S, Aljurf M, Olson T, Anderson E . Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplant Cell Ther. 2021; 28(2):101.e1-101.e6. PMC: 8816844. DOI: 10.1016/j.jtct.2021.10.009. View

Jalas C, Anderson S, Laufer T, Martimucci K, Bulanov A, Xie X . A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population. Blood Cells Mol Dis. 2011; 47(1):79-83. DOI: 10.1016/j.bcmd.2011.03.006. View

Rose M, Nicol K, Skeens M, Gross T, Kerlin B . Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics. Pediatr Blood Cancer. 2008; 50(6):1263-5. DOI: 10.1002/pbc.21453. View

10.

Muraoka K, Ishii E, Tsuji K, Yamamoto S, Yamaguchi H, Hara T . Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol. 1997; 96(2):287-92. DOI: 10.1046/j.1365-2141.1997.d01-2028.x. View

11.

Wicke D, Meyer J, Buesche G, Heckl D, Kreipe H, Li Z . Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia. Mol Ther. 2009; 18(2):343-52. PMC: 2839299. DOI: 10.1038/mt.2009.233. View

12.

Woods G, Bajwa R, Rose M . Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature. Pediatr Transplant. 2013; 18(1):E31-4. DOI: 10.1111/petr.12175. View

13.

Takpradit C, Prockop S, Kernan N, Scaradavou A, Curran K, Ruggiero J . Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine. J Pediatr Hematol Oncol. 2018; 40(4):e220-e224. PMC: 5916036. DOI: 10.1097/MPH.0000000000001106. View

14.

Germeshausen M, Ballmaier M . CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients. Haematologica. 2020; 106(9):2439-2448. PMC: 8409039. DOI: 10.3324/haematol.2020.257972. View

15.

Mathiesen S, Sorensen K, Mejdahl Nielsen M, Suominen A, Ifversen M, Grell K . Male Gonadal Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Cross-Sectional, Population-Based Study. Biol Blood Marrow Transplant. 2020; 26(9):1635-1645. DOI: 10.1016/j.bbmt.2020.05.009. View

16.

Olson T, Caselli A, Otsuru S, Hofmann T, Williams R, Paolucci P . Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. Blood. 2013; 121(26):5238-49. PMC: 3695366. DOI: 10.1182/blood-2012-10-463414. View

17.

Pecci A, Ragab I, Bozzi V, De Rocco D, Barozzi S, Giangregorio T . Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim. EMBO Mol Med. 2017; 10(1):63-75. PMC: 5760853. DOI: 10.15252/emmm.201708168. View

18.

Germeshausen M, Ballmaier M . Congenital amegakaryocytic thrombocytopenia - Not a single disease. Best Pract Res Clin Haematol. 2021; 34(2):101286. DOI: 10.1016/j.beha.2021.101286. View

19.

Cleyrat C, Girard R, Choi E, Jeziorski E, Lavabre-Bertrand T, Hermouet S . Gene editing rescue of a novel mutant associated with congenital amegakaryocytic thrombocytopenia. Blood Adv. 2018; 1(21):1815-1826. PMC: 5728092. DOI: 10.1182/bloodadvances.2016002915. View

20.

Kothari A, Ngwube A, Hayashi R, Murray L, Davis J, Haut P . Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015; 21(7):1321-5. DOI: 10.1016/j.bbmt.2015.03.019. View